Drugs / PF-08653944
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07519135 | Apr 2026 → Jul 2027 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT07508241 | Mar 2026 → Jan 2027 expected | obesity disorder | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07400679 | Feb → Sep 2026 overdue | obesity disorder | Pfizer | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07575932 | May 2026 → Aug 2027 expected | metabolic disease, obesity disorder | Pfizer | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07400653 | Feb 2026 → Oct 2027 expected | obesity disorder, type 2 diabetes mellitus | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08653944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07519135 ↗ |
| Route | Subcutaneous | “By Subcutaneous Injection” NCT07400653 ↗ |